Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias

被引：34

作者：

Cheshire, Perdita ^{[1
]}

Ayton, Scott ^{[2
]}

Bertram, Kelly L. ^{[1
,3
]}

Ling, Helen ^{[4
]}

Li, Abi ^{[5
]}

McLean, Catriona ^{[6
]}

Halliday, Glenda M. ^{[7
,8
]}

O'Sullivan, Sean S. ^{[4
,9
]}

Revesz, Tamas ^{[5
]}

Finkelstein, David I. ^{[2
]}

Storey, Elsdon ^{[1
,3
]}

Williams, David R. ^{[1
,3
]}

机构：

[1] Monash Univ, Dept Med Nuerosci, Melbourne, Vic 3004, Australia

[2] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia

[3] Alfred Hosp, Dept Neurol, Melbourne, Vic 3004, Australia

[4] UCL, Inst Neurol, Reta Lila Weston Inst, London, England

[5] UCL, Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England

[6] Alfred Hosp, Anat Pathol, Melbourne, Vic 3004, Australia

[7] Neurosci Res Australia, Sydney, NSW, Australia

[8] Univ New S Wales, Sydney, NSW, Australia

[9] Cork Univ Hosp, Neurosci Dept, Cork, Ireland

来源：

MOVEMENT DISORDERS | 2015年 / 30卷 / 06期

关键词：

Parkinson's disease; levodopa-induced dyskinesias; serotonin; dopamine; striatum; DOPA-INDUCED DYSKINESIA; HEMIPARKINSONIAN RATS; MOTOR COMPLICATIONS; INNERVATION; BRAIN; 5-HYDROXYTRYPTAMINE; TRANSPORTERS; MECHANISMS; EXPRESSION; TERMINALS;

D O I：

10.1002/mds.26144

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Preclinical animal models implicate serotonin neurons in the pathophysiology of levodopa (l-dopa)-induced dyskinesias in Parkinson's disease (PD), but effective treatment remains elusive. We examined the relationship between serotonin and l-dopa-induced dyskinesias in a pathologically confirmed cohort of PD patients. We obtained brain tissue from 44 PD cases and 17 age-matched controls and assessed monoamine levels and the serotonin and dopamine transporters in the striatum, and the extent of dopaminergic and serotonergic cell preservation in the substantia nigra (SN) and the dorsal raphe nuclei (DRN), respectively. As expected, PD patients demonstrated a severe loss of all dopaminergic markers, including dopamine (P<0.0001) and the dopamine transporter (P<0.0001) in the striatum, and dopaminergic neurons (P<0.001) in the SN, compared with controls. Marked serotonin loss was observed in the caudate (but not putamen) in PD patients compared with controls (P<0.001), but no difference was found in the levels of the serotonin transporter in the striatum or density of serotonergic neurons in the DRN between these groups, suggesting a functional but not structural change in the serotonergic system in PD. No difference was seen in levels of serotonergic and dopaminergic markers in the striatum between PD patients with and without dyskinesias, or between cases separated according to the clinical severity of their dyskinesias. The absence of a correlation between striatal serotonin markers and the incidence and severity of l-dopa-induced dyskinesias suggests that an intact and functioning serotonergic system is not a risk factor for developing dyskinesias in PD. (c) 2015 International Parkinson and Movement Disorder Society

引用

页码：796 / 804

页数：9

共 39 条

[1] The use of total protein stains as loading controls: An alternative to high-abundance single-protein controls in semi-quantitative immunoblotting [J].